

# Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C2EFD8D46D39EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: C2EFD8D46D39EN

## Abstracts

The 7 major cutaneous T-cell lymphoma markets reached a value of US\$ 428.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 628.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.55% during 2024-2034.

The cutaneous T-cell lymphoma market has been comprehensively analyzed in IMARC's new report titled "Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cutaneous T-cell lymphoma (CTCL) refers to a rare type of non-Hodgkin's lymphoma that develops in the T-cells of the immune system and affects the skin. Early-stage CTCL may cause symptoms like dry, scaly patches of skin that may resemble eczema or psoriasis. Over time, these patches may become thicker and more widespread, and raised tumors or plaques may develop. Various other indications of the ailment include itching, redness, appearance of small, fluid-filled blisters on the skin, etc. The diagnosis of CTCL typically involves a combination of clinical evaluation, imaging tests, and skin biopsies. A dermatologist or hematologist/oncologist will first evaluate the patient's medical history, perform a physical examination, and review any symptoms or changes in the skin. Numerous imaging procedures, such as CT scans or PET scans, are ordered to assess the extent of the disease and whether it has spread to other parts of the body. A skin biopsy is typically required to confirm the diagnosis of CTCL. Various additional tests, including flow cytometry and molecular genetic testing, are used to further characterize the cancer cells and guide treatment decisions.

The increasing cases of immune system malfunctions that trigger the proliferation of T-cells are primarily driving the cutaneous T-cell lymphoma market. Furthermore, the rising prevalence of chronic skin inflammation, which causes T-cells to accumulate in

the skin, thereby leading to the development of CTCL, is also propelling the market growth. In addition to this, the widespread adoption of topical steroids for reducing itching, redness, and scaling of the skin is acting as another significant growth-inducing factor. Moreover, the inflating demand for systemic chemotherapy on account of its several associated benefits, such as improved survival rates and a reduction in the size and number of skin lesions, is also creating a positive outlook for the market. Apart from this, the emerging popularity of immune checkpoint inhibitors among patients with advanced or refractory disease, which block proteins on the surface of T-cells and prevent them from attacking cancer cells, is further bolstering the market growth. Additionally, the escalating demand for molecular testing, since it can help to distinguish between different subtypes of CTCL and aid in guiding treatment decisions, is expected to drive the cutaneous T-cell lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cutaneous T-cell lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cutaneous T-cell lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cutaneous T-cell lymphoma market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the cutaneous T-cell lymphoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cutaneous T-cell lymphoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cutaneous T-cell lymphoma marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the cutaneous T-cell lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cutaneous T-cell lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cutaneous T-cell lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cutaneous T-cell lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of cutaneous T-cell lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cutaneous T-cell lymphoma by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of cutaneous T-cell lymphoma by type across the seven major markets?

How many patients are diagnosed (2018-2034) with cutaneous T-cell lymphoma across the seven major markets?

What is the size of the cutaneous T-cell lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cutaneous T-cell lymphoma?

What will be the growth rate of patients across the seven major markets?

### Cutaneous T-Cell Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cutaneous T-cell lymphoma drugs across

the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cutaneous T-cell lymphoma market?

What are the key regulatory events related to the cutaneous T-cell lymphoma market?

What is the structure of clinical trial landscape by status related to the cutaneous T-cell lymphoma market?

What is the structure of clinical trial landscape by phase related to the cutaneous T-cell lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the cutaneous T-cell lymphoma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CUTANEOUS T-CELL LYMPHOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
- 4.5 Competitive Intelligence

### **5 CUTANEOUS T-CELL LYMPHOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CUTANEOUS T-CELL LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034?)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034?)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034?)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034?)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034?)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)

- 7.6.6 Diagnosed Cases (2018-2034)
- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034?)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034?)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034?)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 CUTANEOUS T-CELL LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CUTANEOUS T-CELL LYMPHOMA - UNMET NEEDS**

## **10 CUTANEOUS T-CELL LYMPHOMA - KEY ENDPOINTS OF TREATMENT**

## **11 CUTANEOUS T-CELL LYMPHOMA - MARKETED PRODUCTS**



## 11.1 List of Cutaneous T-Cell Lymphoma Marketed Drugs Across the Top 7 Markets

### 11.1.1 Zolinza (Vorinostat) - Merck & Co

#### 11.1.1.1 Drug Overview

#### 11.1.1.2 Mechanism of Action

#### 11.1.1.3 Regulatory Status

#### 11.1.1.4 Clinical Trial Results

#### 11.1.1.5 Sales Across Major Markets

### 11.1.2 Istodax (Romidepsin) - Celgene Corporation

#### 11.1.2.1 Drug Overview

#### 11.1.2.2 Mechanism of Action

#### 11.1.2.3 Regulatory Status

#### 11.1.2.4 Clinical Trial Results

#### 11.1.2.5 Sales Across Major Markets

### 11.1.3 Valchlor (Chlormethine) - Actelion Pharmaceuticals/Helsinn

#### 11.1.3.1 Drug Overview

#### 11.1.3.2 Mechanism of Action

#### 11.1.3.3 Regulatory Status

#### 11.1.3.4 Clinical Trial Results

#### 11.1.3.5 Sales Across Major Markets

### 11.1.4 Ontak (Denileukin diftitox) - Eisai

#### 11.1.4.1 Drug Overview

#### 11.1.4.2 Mechanism of Action

#### 11.1.4.3 Regulatory Status

#### 11.1.4.4 Clinical Trial Results

#### 11.1.4.5 Sales Across Major Markets

### 11.1.5 Poteligeo (Mogamulizumab) - Kyowa Kirin

#### 11.1.5.1 Drug Overview

#### 11.1.5.2 Mechanism of Action

#### 11.1.5.3 Regulatory Status

#### 11.1.5.4 Clinical Trial Results

#### 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## 12 CUTANEOUS T-CELL LYMPHOMA - PIPELINE DRUGS

### 12.1 List of Cutaneous T-Cell Lymphoma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 IPH4102 - Innate Pharma

##### 12.1.1.1 Drug Overview

- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 CDK-003 - Codiak BioSciences
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 SGX301 - Soligenix
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Resminostat - 4SC
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 WP1220 - Moleculin Biotech
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. CUTANEOUS T-CELL LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. CUTANEOUS T-CELL LYMPHOMA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration

## 14.4 Key Regulatory Events

# 15 CUTANEOUS T-CELL LYMPHOMA - MARKET SCENARIO

## 15.1 Market Scenario - Key Insights

## 15.2 Market Scenario - Top 7 Markets

### 15.2.1 Cutaneous T-Cell Lymphoma - Market Size

#### 15.2.1.1 Market Size (2018-2023)

#### 15.2.1.2 Market Forecast (2024-2034?)

### 15.2.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies

#### 15.2.2.1 Market Size by Therapies (2018-2023)

#### 15.2.2.2 Market Forecast by Therapies (2024-2034?)

## 15.3 Market Scenario - United States

### 15.3.1 Cutaneous T-Cell Lymphoma - Market Size

#### 15.3.1.1 Market Size (2018-2023)

#### 15.3.1.2 Market Forecast (2024-2034?)

### 15.3.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies

#### 15.3.2.1 Market Size by Therapies (2018-2023)

#### 15.3.2.2 Market Forecast by Therapies (2024-2034?)

### 15.3.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 Cutaneous T-Cell Lymphoma - Market Size

#### 15.4.1.1 Market Size (2018-2023)

#### 15.4.1.2 Market Forecast (2024-2034?)

### 15.4.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (2018-2023)

#### 15.4.2.2 Market Forecast by Therapies (2024-2034?)

### 15.4.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 Cutaneous T-Cell Lymphoma - Market Size

#### 15.5.1.1 Market Size (2018-2023)

#### 15.5.1.2 Market Forecast (2024-2034?)

### 15.5.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (2018-2023)

#### 15.5.2.2 Market Forecast by Therapies (2024-2034?)

### 15.5.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 Cutaneous T-Cell Lymphoma - Market Size

#### 15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034?)
- 15.6.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034?)
- 15.6.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Cutaneous T-Cell Lymphoma - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034?)
  - 15.7.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.7.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Cutaneous T-Cell Lymphoma - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034?)
  - 15.8.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.8.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Cutaneous T-Cell Lymphoma - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034?)
  - 15.9.2 Cutaneous T-Cell Lymphoma - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034?)
  - 15.9.3 Cutaneous T-Cell Lymphoma - Access and Reimbursement Overview

## **16 CUTANEOUS T-CELL LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CUTANEOUS T-CELL LYMPHOMA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 CUTANEOUS T-CELL LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Cutaneous T-Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C2EFD8D46D39EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2EFD8D46D39EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

